diabetes treatments

Drugs like Ozempic are revolutionizing the treatment of obesity. The medications, originally used to treat diabetes, keep gaining attention as celebrities and other influencers describe taking them to lose weight quickly.

Dani Blum, a reporter for The Times, tells the story behind the drugs and describes some of the ramifications of using them.

Guest: Dani Blum, a reporter for Well at The New York Times.

Background reading: 

• Ozempic can cause major weight loss. What happens if you stop taking it?
• Some people taking the drugs can experience such intense lack of appetite that they become malnourished.

For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

There's a new class of weight-loss drugs in town. GLP-1 medications including Ozempic, Wegovy and Mounjaro were created to treat diabetes but have since been found to suppress appetites and induce substantial weight loss. It's a big deal for the companies which make them, with shares of Novo Nordisk and Eli Lilly all soaring in recent weeks. But the drugs could end up having a much broader economic impact too. On this episode, we speak with James van Geelen of Citrinitas Capital, about the second-order effects of effective weight-loss drugs. He talks us through how he's evaluating the potential of the new meds and how he approaches possible 'mega-trends' like GLP-1 or AI.

See omnystudio.com/listener for privacy information.